NAPLEX Quiz: Root Cause Analysis

What this quiz covers

This quiz focuses on Root Cause Analysis, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Excess thyroid hormone from levothyroxine overdose causing iatrogenic hyperthyroidism
2. Stimulant adverse effects from the OTC supplement causing sympathetic activation (correct answer)
3. Oral contraceptive-induced thyrotoxicosis due to increased free T4
4. Acute allergic reaction to levothyroxine excipients

Explanation: This question tests root cause analysis in distinguishing medication adverse effects from underlying conditions in symptomatic patients. The key patient-specific factor is the initiation of an OTC supplement containing stimulants like caffeine and yohimbine, mimicking hyperthyroidism symptoms. Choice B correctly identifies the root cause as stimulant-induced sympathetic activation, explaining tachycardia and insomnia with normal TSH. Choice A is incorrect as levothyroxine dose is stable without overdose signs, and choice C is suboptimal because oral contraceptives increase binding proteins but not free T4 toxicity. Choice D is wrong as allergies to levothyroxine are rare and not acute. A clinical pearl is to inquire about OTC products in root cause analysis, using timelines to correlate symptom onset. Evidence-based decision-making involves lab confirmation to rule out endogenous causes.

Question 2

1. Rifampin induces metabolism of fluconazole, decreasing antifungal exposure and efficacy (correct answer)
2. Oral contraceptives inactivate fluconazole through chelation, preventing absorption
3. Fluconazole is ineffective for Candida species and should never be used for vaginitis
4. A single dose of fluconazole always requires coadministration with a probiotic to work

Explanation: This question tests root cause analysis of antifungal treatment failure due to a significant drug interaction affecting fluconazole efficacy. The key patient-specific factor is the concurrent use of rifampin, a potent enzyme inducer that increases the metabolism of many drugs including fluconazole. The correct answer (A) identifies that rifampin induces CYP450 enzymes responsible for fluconazole metabolism, significantly reducing antifungal exposure and therapeutic efficacy, explaining persistent symptoms despite treatment. Option B is incorrect because oral contraceptives do not chelate or inactivate fluconazole. Option C is incorrect as fluconazole is highly effective for most Candida species causing vulvovaginal candidiasis. Option D is incorrect because single-dose fluconazole is effective without probiotics, though they may provide adjunctive benefit. The clinical pearl is that rifampin is one of the most potent enzyme inducers in clinical use, requiring dose adjustments or alternative agents for many concurrent medications, with effects persisting for weeks after discontinuation due to enzyme auto-induction.

Question 3

1. Starting potassium chloride 20 mEq daily leading to hyperkalemia and worsened conduction abnormalities
2. Increasing digoxin to 0.25 mg daily despite worsening renal function, increasing digoxin exposure (correct answer)
3. Continuing metoprolol succinate 100 mg daily causing acute cholestatic hepatitis
4. Continuing lisinopril 20 mg daily causing symptomatic hypoglycemia

Explanation: This question tests root cause analysis of digoxin toxicity in the setting of worsening renal function. The key patient-specific factor is the recent increase in digoxin dose from 0.125 mg to 0.25 mg daily 10 days ago, combined with worsening renal function (SCr increased from 1.4 to 2.0 mg/dL), which significantly reduces digoxin clearance. The correct answer (B) identifies that increasing digoxin despite worsening renal function led to drug accumulation and classic toxicity symptoms including nausea, confusion, and yellow-green visual halos. Option A is incorrect because while the patient has hypokalemia (K 3.1), not hyperkalemia, and potassium supplementation would be appropriate. Option C is incorrect as metoprolol does not commonly cause cholestatic hepatitis, and liver enzymes are normal. Option D is incorrect because ACE inhibitors do not cause hypoglycemia. The clinical pearl is that digoxin has a narrow therapeutic index and requires dose adjustment for renal function, with toxicity risk increased by hypokalemia and hypomagnesemia, both present in this patient.

Question 4

1. Adding tiotropium causing beta-agonist toxicity and hypokalemia
2. Adding frequent albuterol nebulizer use on top of albuterol inhaler leading to excessive beta-2 agonist effects (correct answer)
3. Continuing fluticasone/salmeterol causing acute opioid withdrawal symptoms
4. Prednisone course completed 10 days ago causing persistent adrenal crisis and tachycardia

Explanation: This question tests root cause analysis of beta-agonist toxicity from additive therapy in COPD management. The key patient-specific factor is the addition of scheduled albuterol nebulizer treatments to a regimen already containing both short-acting (albuterol HFA) and long-acting (salmeterol) beta-agonists. The correct answer (B) identifies that frequent albuterol nebulizer use on top of existing beta-agonist therapy led to excessive beta-2 stimulation, causing classic toxicity symptoms including tremor, tachycardia (HR 112), hypertension, hypokalemia (K 3.2), and insomnia. Option A is incorrect because tiotropium is an anticholinergic that doesn't cause beta-agonist toxicity. Option C is incorrect as fluticasone/salmeterol doesn't cause opioid withdrawal. Option D is incorrect because completed prednisone courses don't cause persistent adrenal crisis 10 days later. The clinical pearl is that beta-agonist effects are additive across all formulations, and patients on LABA therapy should use SABA rescue medications judiciously, with careful monitoring for signs of excessive beta-stimulation including electrolyte abnormalities.

Question 5

1. Allopurinol is ineffective because uric acid is already at goal, so gout flares cannot occur
2. Initiation of urate-lowering therapy without anti-inflammatory prophylaxis leading to early gout flares (correct answer)
3. Losartan causes uric acid retention, worsening gout despite allopurinol
4. Metformin precipitates monosodium urate crystals and directly triggers gout attacks

Explanation: This question tests root cause analysis of paradoxical gout flares during initiation of urate-lowering therapy. The key patient-specific factor is starting allopurinol without concurrent anti-inflammatory prophylaxis, after the patient discontinued colchicine due to GI intolerance. The correct answer (B) identifies that initiating urate-lowering therapy causes rapid changes in serum uric acid levels, which can mobilize tissue deposits and paradoxically trigger acute flares in the first few months of treatment, despite improving uric acid levels (6.2 mg/dL). Option A is incorrect because gout flares commonly occur during early treatment even when uric acid reaches goal. Option C is incorrect as losartan actually has mild uricosuric effects and doesn't worsen gout. Option D is incorrect because metformin doesn't precipitate urate crystals or trigger gout. The clinical pearl is that anti-inflammatory prophylaxis (colchicine, NSAIDs, or low-dose corticosteroids) should be continued for 3-6 months when initiating urate-lowering therapy, with alternatives like low-dose NSAIDs or corticosteroids available for colchicine-intolerant patients.

Question 6

1. Ibuprofen use causing reduced antihypertensive/diuretic effectiveness and worsening renal function (correct answer)
2. Hydrochlorothiazide onset is delayed for 6 months, so blood pressure cannot improve yet
3. Amlodipine causes hyperkalemia, preventing lisinopril from working
4. Lisinopril requires coadministration with potassium supplements to lower blood pressure

Explanation: This question tests root cause analysis of antihypertensive failure due to NSAID interference with multiple drug classes. The key patient-specific factor is the addition of high-dose ibuprofen (600 mg TID) to a regimen containing an ACE inhibitor, diuretic, and baseline CKD. The correct answer (A) identifies that NSAIDs reduce the effectiveness of ACE inhibitors and diuretics through prostaglandin inhibition, while also worsening renal function (SCr increased from 1.0 to 1.4) and causing hyperkalemia (K 5.3) through reduced renal potassium excretion. Option B is incorrect because hydrochlorothiazide works within days to weeks, not months. Option C is incorrect as amlodipine causes hypokalemia, not hyperkalemia, and doesn't prevent ACE inhibitor efficacy. Option D is incorrect because ACE inhibitors work independently of potassium supplementation. The clinical pearl is that NSAIDs antagonize most antihypertensive drug classes except calcium channel blockers, with particular risk in elderly patients with CKD, often requiring alternative pain management strategies like acetaminophen or topical agents.

Question 7

1. Poor adherence to furosemide due to complex dosing schedule
2. NSAID-related sodium/water retention and reduced diuretic/ACE inhibitor effectiveness (correct answer)
3. Carvedilol causing acute fluid overload due to beta-blockade
4. Lisinopril causing diuresis leading to dehydration and prerenal azotemia

Explanation: This question tests root cause analysis in evaluating factors impairing heart failure management and diuretic efficacy. The key patient-specific factor is the addition of ibuprofen, which antagonizes the effects of furosemide and lisinopril through prostaglandin inhibition. Choice B correctly identifies the root cause as NSAID-induced sodium retention and reduced drug effectiveness, leading to edema and elevated SCr. Choice A is incorrect as there's no evidence of poor adherence, and choice C is suboptimal because carvedilol does not cause acute fluid overload. Choice D is wrong as lisinopril does not typically cause dehydration here. A transferable framework is to screen for OTC NSAIDs in heart failure patients using the '5 Whys' technique to uncover hidden contributors. Thorough investigation promotes evidence-based avoidance of NSAIDs to optimize therapy.

Question 8

1. Recommend increasing lamotrigine dose immediately because valproic acid lowers lamotrigine concentrations
2. Identify the interaction where valproic acid increases lamotrigine exposure and coordinate dose adjustment and monitoring (correct answer)
3. Discontinue sertraline because it is the most common cause of breakthrough seizures
4. Advise the patient to take lamotrigine with food to prevent seizures caused by rapid absorption

Explanation: This question tests root cause analysis of breakthrough seizures due to incomplete medication reconciliation and a significant antiepileptic drug interaction. The key patient-specific factor is the addition of valproic acid to stable lamotrigine therapy without appropriate dose adjustment, where valproic acid inhibits lamotrigine glucuronidation, approximately doubling its half-life and exposure. The correct answer (B) identifies the need to recognize this interaction and coordinate dose reduction of lamotrigine (typically by 50%) with close monitoring for both efficacy and toxicity. Option A is incorrect because valproic acid increases, not decreases, lamotrigine concentrations. Option C is incorrect as sertraline rarely affects seizure control at therapeutic doses. Option D is incorrect because lamotrigine absorption is not significantly affected by food, and this wouldn't address the underlying interaction. The clinical pearl is that medication reconciliation failures during care transitions are a leading cause of preventable adverse events, and pharmacists play a crucial role in identifying and managing complex drug interactions, particularly with narrow therapeutic index medications like antiepileptics.

Question 9

1. Cefepime neurotoxicity due to lack of renal dose adjustment in severe renal impairment (correct answer)
2. Sevelamer causing acute encephalopathy through systemic absorption
3. Amlodipine causing myoclonus due to calcium channel blockade
4. UTI progression causing seizures despite appropriate antibiotic dosing

Explanation: This question assesses root cause analysis for identifying drug-induced neurotoxicity in a patient with chronic kidney disease receiving intravenous antibiotics. The key patient-specific factor is the inappropriate dosing of cefepime without renal adjustment, given the patient's estimated creatinine clearance of approximately 18 mL/min, leading to drug accumulation. The correct answer, cefepime neurotoxicity due to lack of renal dose adjustment in severe renal impairment, pinpoints the root cause as it explains how excessive cefepime levels can cause encephalopathy and myoclonus, necessitating immediate dose reduction or discontinuation to resolve symptoms. Sevelamer and amlodipine are incorrect distractors because sevelamer is not systemically absorbed and amlodipine does not typically induce myoclonus, addressing the misconception that all medications in renal patients contribute equally to neurological issues. UTI progression is suboptimal as the symptoms align more with beta-lactam toxicity than infection worsening, a common error in overlooking pharmacokinetic adjustments in impaired clearance. A transferable clinical pearl is to employ a structured root cause analysis framework, including evaluating renal function, drug dosing guidelines, and temporal symptom onset, to differentiate drug-related from disease-related adverse events. This method underscores the critical role of thorough pharmacokinetic assessment and evidence-based interventions in ensuring patient safety during antimicrobial therapy in pharmacy practice.

Question 10

1. Additive vasodilation and hypotension from concurrent PDE5 inhibitor and alpha-1 blocker use (correct answer)
2. Hydrochlorothiazide causing acute hypoglycemia leading to syncope
3. Tamsulosin causing hypertensive crisis when combined with sildenafil
4. Sildenafil causing bradycardia due to beta-blockade

Explanation: This question tests root cause analysis in vasodilator interactions causing hypotension. The key patient-specific factor is combining sildenafil with tamsulosin, amplifying vasodilation. Choice A correctly identifies the root cause as additive effects leading to syncope. Choice B is incorrect as hydrochlorothiazide does not cause hypoglycemia, and choice C is suboptimal because tamsulosin does not cause hypertension. Choice D is wrong as sildenafil lacks beta-blockade. A pearl is to limit sildenafil to 25 mg with alpha-blockers. Thorough counseling supports evidence-based use.

Question 11

1. Additive risk of intracranial hypertension from concomitant isotretinoin and tetracycline therapy (correct answer)
2. Oral contraceptive failure leading to early pregnancy symptoms
3. Isotretinoin-induced hypoglycemia causing neuroglycopenic symptoms
4. Doxycycline causing acute angle-closure glaucoma in most patients

Explanation: This question tests root cause analysis in recognizing drug interactions causing pseudotumor cerebri in acne treatment. The key patient-specific factor is the concurrent use of isotretinoin and doxycycline, both linked to intracranial hypertension. Choice A correctly identifies the root cause as additive risk leading to headaches and vision changes. Choice B is incorrect as pregnancy is ruled out, and choice C is suboptimal because isotretinoin does not cause hypoglycemia. Choice D is wrong as doxycycline rarely causes glaucoma. A clinical pearl is to avoid tetracyclines with isotretinoin per guidelines. Evidence-based monitoring includes symptom timelines for prompt resolution.

Question 12

1. Recommend increasing alosetron dose to improve bowel motility
2. Advise immediate discontinuation and urgent evaluation for ischemic colitis/serious constipation risk with alosetron (correct answer)
3. Add diphenoxylate/atropine to control diarrhea and reduce cramping
4. Switch amitriptyline to a higher dose to counteract constipation

Explanation: This question tests root cause analysis in recognizing serious adverse effects of IBS medications. The key patient-specific factor is alosetron's risk of ischemic colitis or severe constipation in susceptible patients. Choice B correctly identifies the root cause by recommending discontinuation to prevent complications. Choice A is incorrect as increasing alosetron worsens risks, and choice C is suboptimal because adding diphenoxylate increases constipation. Choice D is wrong as amitriptyline dose escalation is not indicated. A pearl is to monitor for constipation in 5-HT3 antagonists. Thorough evaluation ensures evidence-based safety.

Question 13

1. Phenytoin toxicity due to antibiotic-related alteration of metabolism or protein binding leading to elevated levels (correct answer)
2. Amoxicillin/clavulanate causing predictable cerebellar toxicity at standard doses
3. Famotidine causing phenytoin malabsorption leading to withdrawal seizures
4. Sinusitis progression causing neurologic deficits unrelated to medications

Explanation: This question tests root cause analysis in antibiotic interactions elevating anticonvulsant levels. The key patient-specific factor is amoxicillin/clavulanate displacing phenytoin from protein binding. Choice A correctly identifies the root cause as toxicity from high phenytoin levels causing neurologic symptoms. Choice B is incorrect as amoxicillin/clavulanate does not cause cerebellar toxicity, and choice C is suboptimal because famotidine does not affect absorption. Choice D is wrong as sinusitis does not cause these deficits. A framework monitors levels post-antibiotic start. Evidence-based adjustments prevent toxicity.

Question 14

1. Additive gastrointestinal bleeding risk from dual antiplatelet therapy plus NSAID use (correct answer)
2. Omeprazole causing peptic ulcer disease by increasing gastric acid secretion
3. Clopidogrel causing dark stools due to harmless stool discoloration
4. Aspirin causing constipation leading to black stools

Explanation: This question tests root cause analysis in antiplatelet and NSAID combinations increasing GI bleed risk. The key patient-specific factor is adding daily naproxen to dual antiplatelet therapy post-TIA. Choice A correctly identifies the root cause as additive bleeding risk despite omeprazole. Choice B is incorrect as omeprazole suppresses acid, and choice C is suboptimal because clopidogrel does not discolor stools. Choice D is wrong as aspirin causes bleeding, not constipation. A pearl is to avoid NSAIDs in high-risk patients. Evidence-based alternatives like acetaminophen prevent recurrence.

Question 15

1. Propranolol antagonizing beta-2 receptors leading to bronchospasm and reduced bronchodilator response (correct answer)
2. Formoterol causing paradoxical bronchospasm due to LABA class effect in all patients
3. Budesonide causing acute airway inflammation from steroid hypersensitivity
4. Albuterol overuse causing long-term airway remodeling within 4 weeks

Explanation: This question tests root cause analysis in beta-blockers exacerbating respiratory conditions. The key patient-specific factor is initiating non-selective propranolol in an asthma patient, blocking beta-2 receptors. Choice A correctly identifies the root cause as bronchospasm reducing asthma control. Choice B is incorrect as formoterol does not cause paradoxical effects routinely, and choice C is suboptimal because budesonide hypersensitivity is rare. Choice D is wrong as albuterol overuse takes longer for remodeling. A framework assesses selectivity in beta-blockers for asthmatics. Thorough review optimizes evidence-based therapy.

Question 16

1. Bradykinin-mediated angioedema from ACE inhibitor initiation (correct answer)
2. IgE-mediated anaphylaxis to atorvastatin after long-term use
3. Dose-related edema from amlodipine causing facial swelling within hours
4. Rebound hypertension causing cough and swelling due to medication nonadherence

Explanation: This question tests root cause analysis in rapid-onset adverse effects from ACE inhibitors. The key patient-specific factor is the first dose of lisinopril triggering bradykinin accumulation. Choice A correctly identifies the root cause as angioedema presenting as cough and swelling. Choice B is incorrect as anaphylaxis to atorvastatin is unlikely after long use, and choice C is suboptimal because amlodipine edema is peripheral and delayed. Choice D is wrong without adherence issues. A framework recognizes class effects in hypertensives. Thorough monitoring ensures evidence-based switching to ARBs.

Question 17

1. Allopurinol inhibition of xanthine oxidase increasing azathioprine/6-MP levels causing myelosuppression (correct answer)
2. Lisinopril-induced aplastic anemia due to ACE inhibitor class effect
3. Allopurinol causing folate deficiency leading to pancytopenia
4. Azathioprine underdosing leading to uncontrolled IBD and secondary anemia

Explanation: This question tests root cause analysis in pharmacokinetic interactions enhancing immunosuppressant toxicity. The key patient-specific factor is starting azathioprine without adjusting for allopurinol's xanthine oxidase inhibition. Choice A correctly identifies the root cause as increased 6-MP levels causing myelosuppression. Choice B is incorrect as lisinopril rarely causes aplastic anemia, and choice C is suboptimal because allopurinol does not deplete folate. Choice D is wrong as azathioprine is not underdosed. A pearl is to reduce azathioprine dose by 75% with allopurinol. Evidence-based monitoring prevents severe ADRs.

Question 18

1. Insulin glargine requires twice-daily dosing in all patients
2. Improper insulin storage leading to reduced potency and inadequate glycemic control (correct answer)
3. Metformin causing hyperglycemia due to hepatic enzyme induction
4. Lisinopril worsening insulin resistance through beta-blockade

Explanation: This question tests root cause analysis in pinpointing storage-related issues affecting insulin efficacy in diabetes management. The key patient-specific factor is improper storage of insulin glargine in a hot car, degrading its potency. Choice B correctly identifies the root cause as reduced insulin activity leading to hyperglycemia despite initiation. Choice A is incorrect as glargine is once-daily, and choice C is suboptimal because metformin does not induce hyperglycemia. Choice D is wrong as lisinopril is not a beta-blocker. A transferable framework is to educate on storage conditions during dispensing. Thorough investigation of lifestyle factors ensures evidence-based glycemic control.

Question 19

1. IgE-mediated allergy to niacin requiring lifelong avoidance of all B vitamins
2. Prostaglandin-mediated niacin flushing, more likely with higher doses and without premedication (correct answer)
3. Rosuvastatin-induced urticaria due to cumulative statin exposure
4. Aspirin-induced histamine release causing acute hives after niacin initiation

Explanation: This question tests root cause analysis in differentiating predictable side effects from allergies in lipid therapy. The key patient-specific factor is the high initial dose of niacin without premedication, triggering flushing. Choice B correctly identifies the root cause as prostaglandin-mediated reaction, common with niacin. Choice A is incorrect as niacin reactions are not IgE-mediated, and choice C is suboptimal because rosuvastatin rarely causes urticaria. Choice D is wrong as aspirin mitigates, not causes, flushing. A clinical pearl is to start niacin low and use aspirin prophylaxis. Evidence-based counseling prevents mislabeling as allergy.

Question 20

1. Inappropriate storage of the in-use insulin pen in the freezer, reducing insulin potency (correct answer)
2. Metformin ER dose is too high and is causing insulin resistance
3. Semaglutide is contraindicated with insulin glargine and blocks its absorption
4. Injecting insulin into the upper arm is never effective due to lack of subcutaneous tissue

Explanation: This question tests root cause analysis of insulin therapy failure due to improper storage and administration technique. The key patient-specific factor is the patient's report of storing her in-use insulin pen in the freezer, which causes insulin to denature and lose potency. The correct answer (A) identifies that freezing insulin renders it ineffective, explaining why glucose remains elevated despite dose increases. Option B is incorrect because metformin does not cause insulin resistance and the dose is appropriate. Option C is incorrect as semaglutide and insulin glargine can be used together safely and do not interact. Option D is incorrect because the upper arm is an acceptable injection site with adequate subcutaneous tissue in most patients. The clinical pearl is that proper insulin storage (room temperature for in-use pens, refrigerated but not frozen for unopened vials) and injection technique (rotating sites, not rubbing after injection) are essential for therapeutic success. Pharmacists should always assess storage and administration when patients report poor glycemic control despite adherence.